All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2008-006831-10 | Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con c... | 2016-09-26 | due-trials |
| Reported results | 2009-013157-15 | A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca... | 2018-08-21 | due-trials |
| Reported results | 2009-013788-21 | A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis | 2016-09-26 | due-trials |
| Reported results | 2009-015476-98 | LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prio... | 2018-07-26 | due-trials |
| Reported results | 2009-016178-33 | A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in typ... | 2015-09-22 | due-trials |
| Reported results | 2009-016244-39 | A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension per... | 2015-08-28 | due-trials |
| Ongoing | 2009-017661-34 | An open label trial of afatinib (Giotrif) in treatment-naive (1st line) or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutat... | not-yet-due | |
| Reported results | 2009-018197-66 | Ensayo clínico de seguridad, efecto antiviral y farmacocinética de BI 207127 en combinación con BI 201335 y con Ribavirina durante 4 semanas (Parte 1) y con o sin ribavirina durante 24-48 semanas (Par... | 2014-10-30 | due-trials |
| Reported results | 2011-000392-14 | A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients w... | 2016-09-12 | due-trials |
| Reported results | 2011-001758-26 | A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in t... | 2015-12-08 | due-trials |
| Reported results | 2011-002380-24 | LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-b... | 2017-12-27 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2011-002766-21 | An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) Studio clinico di estensione in aperto per la valutazione della sicurez... | 2021-02-01 | bad-data |
| Reported results | 2012-000095-42 | A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies... | 2016-09-15 | due-trials |
| Reported results | 2012-002271-34 | A phase III, randomized, double-blind, parallel group study to evaluate the efficacy and safety of linagliptin 5 mg compared to placebo, administered as oral fixed dose combination with empagliflozin ... | 2015-03-13 | due-trials |
| Reported results | 2012-002487-27 | A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients >= 6... | 2021-05-28 | due-trials |
| Reported results | 2012-003533-41 | A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infectio... | 2015-03-11 | due-trials |
| Reported results | 2012-003535-27 | A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended popu... | 2015-03-11 | due-trials |
| Reported results | 2012-005201-48 | Double blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrex... | 2018-08-28 | due-trials |
| Reported results | 2013-002671-18 | An explorarory, 12 week, randomised, partially double-blinded, placebo-controlled parallel group trial to explore the effects of once daily treatments of orally inhaled tiotropium + olodaterol fixed d... | 2015-10-31 | due-trials |
| Reported results | 2013-003201-26 | A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl... | 2017-06-05 | due-trials |
| Reported results | 2013-003444-24 | Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetyls... | 2018-10-10 | due-trials |
| Reported results | 2013-004813-41 | A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ete... | 2016-10-20 | due-trials |
| Reported results | 2013-005031-24 | A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t... | 2017-10-09 | due-trials |
| Reported results | 2013-005040-28 | A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t... | 2017-10-10 | due-trials |
| Reported results | 2014-002275-28 | A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared ... | 2017-03-29 | due-trials |
| Reported results | 2014-005256-26 | A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of empagliflozin as adjunctive to insulin therapy over 26 w... | 2017-12-28 | due-trials |
| Reported results | 2015-000392-28 | A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ... | 2018-11-28 | due-trials |
| Reported results | 2015-001750-15 | A double-blind, randomised, placebo-controlled trial evaluating the effect of BI 655064 administered as sub-cutaneous injections, on renal response after one year of treatment, in patients with active... | 2020-08-18 | due-trials |
| Reported results | 2015-003529-33 | A randomized, double-masked, placebo-controlled exploratory study to evaluate pharmacodynamics, safety and tolerability of orally administered BI 1026706 for 12 weeks in patients with mild visual impa... | 2017-10-24 | due-trials |
| Reported results | 2015-003622-13 | BI 655066 (risankinumab) versus Ustekinumab and placebo comparators in a randomized double blind trIal for Maintenance use in Moderate to severe plaque type psoriasis-2 (UltIMMa-2) Studio randomizz... | 2017-09-04 | due-trials |
| Reported results | 2015-003623-65 | 655066/ABBV-006 (risankizumab)versus adalimumab in a randomized, double blind, parallel group trial in moderate to severe plaque psoriasis to assess safety and efficacy after 16 weeks of treatment and... | 2017-08-27 | due-trials |
| Reported results | 2015-004412-38 | RE-SPECT CVT: a randomised, open-label, exploratory trial with blinded endpoint adjudication (PROBE), comparing efficacy and safety of oral dabigatran etexilate versus oral warfarin in patients with c... | 2018-06-27 | due-trials |
| Trial is partly outside EEC, and reported results | 2016-000669-21 | A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety ext... | 2023-05-31 | bad-data |
| Reported results | 2016-002971-91 | A Randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of Orally administered BI 1467335 for 12 weeks with a 12 week ... | 2020-05-14 | due-trials |
| Reported results | 2017-004072-59 | A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie... | 2019-10-09 | due-trials |
| Reported results | 2017-004073-14 | A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie... | 2019-10-07 | due-trials |
| Reported results | 2019-004749-33 | An open label, randomized Phase II study of BI 754091 alone or in combination with BI 836880 in patients with chemotherapy resistant, unresectable, metastatic squamous cell carcinoma of the anal canal | 2020-11-19 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2020-002913-16 | The TRISTARDS trial - ThRombolysIS Therapy for ARDS A Phase IIb/III operationally seamless, open-label, randomised, sequential, parallel-group adaptive study to evaluate the efficacy and safety of dai... | 2022-07-25 | bad-data |